Lubiprostone

Lubiprostone is a clinically approved, small-molecule chloride channel activator used for the treatment of chronic idiopathic constipation and opioid-induced constipation . The therapeutic mechanism of Lubiprostone involves the specific activation of ClC-2 chloride channels in the intestinal epithelial cells. By binding to these channels, Lubiprostone increases chloride ion secretion into the gut lumen, creating an osmotic gradient that draws water across the intestinal wall . This action enhances the fluid content of the stool, improves intestinal motility, and facilitates bowel movements. The FDA-approved indications for Lubiprostone include chronic idiopathic constipation and opioid-induced constipation, and it has also been investigated for the treatment of irritable bowel syndrome with constipation . The unique mechanism of action of Lubiprostone, as a prostaglandin-derived chloride channel activator, distinguishes it from other laxatives that primarily act as osmotics or stimulants.

Product Parameters

Pharmacological Action

Lubiprostone is a localized chloride channel activator that selectively activates type 2 chloride channels (CClC-2) located on the apical luminal membrane of gastrointestinal epithelial cells, increasing intestinal fluid secretion and intestinal motility, thereby promoting defecation and alleviating symptoms of chronic idiopathic constipation, without altering the plasma concentrations of sodium and potassium.

Drug-related Effects

In vitro tests confirm that the probability of interaction between this product and other drugs is very low. In vitro studies on liver microsomes show that carbonyl reductase plays a role in the biotransformation of this drug, and meanwhile, this drug neither induces nor inhibits cytochrome P450 enzymes, including 3A4, 2D6, 1A2, 2A6, 2B6, 2C9, 2C19, 2E1, etc.

Product Quality Assurance

Cosperpharm has established a comprehensive quality assurance system for Lubiprostone that meets the rigorous expectations of pharmaceutical research:

Thorough analytical characterization. Each batch undergoes multi-technique analytical release testing: HPLC purity verification, appearance verification, and identity confirmation.

Full batch traceability with retention samples. From raw material procurement through synthesis and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with sufficient retention samples maintained in accordance with Cosperpharm quality procedures.

Documentation ready for regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch-specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery.

Contact Us

Ready to source Lubiprostone for your gastrointestinal research or drug development program? Cosperpharm is your trusted partner for high-quality prostaglandin derivatives. Contact us today to discuss your requirements.